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Premature death from cardiovascular disease is especially high in patients with
chronic kidney disease (CKD). Vascular calcification is a potent risk factor for
developing cardiac-related morbidity and mortality and is especially prominent within the
CKD population. Deficiencies in serum levels of fetuin-A as well as inadequate
production of matrix Gla protein (MGP) correlate inversely with the extent of vascular
calcification and time spent on dialysis. Fetuin-A is a well-known systematic regulator of
bone metabolism and MGP is a local antagonist of bone forming proteins. To meet the
clinical need of at-risk patients prone to cardiac-related mortality. We propose a targeted
protein therapy to treat arteriosclerotic arteries. The focus of this thesis was to
characterize the binding interactions of fetuin-A with calcium mineral in a simulated
body fluid and to study the in vitro effects of a fetuin vitamin K2 co-therapy on the
prevention of calcification of vascular smooth muscle cells.
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CHAPTER I
CARDIO-RENAL SYNDROME

Statistics from the 2012 American Heart Association report show that each
minute an American dies of a heart disease-related event [1]. Annually, cardiovascular
disease is the cause of 1 in every 4 deaths in the United States [1]. Cardiovascular disease
is also the leading cause of mortality for patients at all stages of chronic kidney disease
(CKD), accounting for over fifty percent of mortality [2, 3]. Patients with CKD are more
likely to die of cardiac related health events than to even reach end-stage renal disease
(ESRD) [2].
Longitudinal studies show that around thirty percent of the population suffering
from cardiovascular disease also ends up with concurrent CKD [4]. This dynamic
pathophysiological disorder of the heart and kidneys has been termed cardio-renal
syndrome [4]. In recent years, studies have identified the following mutual risk factors
that increase the morbidity among populations that suffer from cardio-renal syndrome:
hypertension, diabetes, dyslipidemia, obesity, left ventricular hypertrophy, and vascular
calcification [5-11]. In addition to the afore mentioned ‘traditional’ risk factors patients
with CKD must also take into consideration the following kidney specific risk factors:
proteinuria, anemia, inflammation, oxidative stress, mineral metabolism imbalance, high
parathyroid hormone and low serum fetuin-A levels, and time on dialysis [12-20]. Heart
failure at the onset of dialysis treatments in ESRD patients increases both the risk of early
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death, death within 90 days of starting dialysis, and also long-term mortality [21]. A 2009
study reports that after 3 years the heart failure mortality rate of dialysis patients was
83% [21].
On average of 60-80% of dialysis patients experience severe vascular calcification
contributing to cardiac morbidity and mortality where an estimated 50% of all ESRD
mortality is caused by cardiovascular disease [2]. The U.S. Department of Health and
Human Services estimates a 1.5 fold increase in ESRD patients by the year 2020; with no
current therapy to treat vascular calcification a targeted therapy for treating the vascular
arterial disease is necessary to maintain patients’ long term survival. The work presented
in this here thesis was designed to address the clinical need of CKD patients with heart
disease. A study of the elevated risk factors that exist for dialysis patients developing
vascular disease, as well as an overview of the underlying biochemical factors were the
basis for this thesis project.
There is a strong clinical need for a minimally invasive therapeutic option to
prevent and repair calcifying arteries without jeopardizing the already at risk patients who
commonly suffer from co-morbidities. Based on current biomedical research findings it is
the goal of this thesis work to show the feasibility of a protein therapy to prevent and or
rescue calcifying vasculature. An intravenous targeted protein therapy could treat
calcification negating any harmful effects of dialysis treatment on the cardiovascular
system and prevent cardiac-related morbidity in already at risk patients with CKD.
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CHAPTER II
VASCULAR CALCIFICATION

There is clinical evidence that at-risk patient groups, like ESRD patients on
dialysis, are at higher risk of developing cardiovascular disease and cardiac-related
mortality due to the extent, severity and accelerated development of vascular calcification
in the layers of the artery walls [22-25]. Vascular calcification (VC) is characterized by
arterial stiffening, elevated systolic pressure and increased cardiac workload [11, 26].
There are two main types of vascular calcification, intimal and medial where the latter is
most frequently observed in dialysis patients. Intimal calcification, or atherosclerosis,
stems from damage to the endothelial lining coupled with an inflammatory and/or
immune response that leads to plaque build-up and subsequent hardening eventually
causing occlusion of the artery [9, 27, 28]. Medial calcification, also known as
Mönckeberg’s sclerosis or arteriosclerosis [29, 30], directly affects the vascular smooth
muscle cells (VSMCs) and is characterized by a loss of functional calcium receptors in
the cell which leads to intercellular mineral imbalance and causes a change in VSMC
phenotype and promotes osteogenic transformation of the VSMCs [12, 31-36]. Thus the
deposition of hydroxyapatite mineral (basic calcium phosphate) within the VSMC matrix
leads to hardening the medial layer and results in a loss of compliance of the artery. Both
clinical studies of calcified arteries and in vitro calcification studies of VSMCs have
shown that mineral imbalance contributes to differentiation of VSMCs into an osteogenic
3

phenotype by down regulating VSMCs contractile proteins and up-regulating bone matrix
proteins, like bone morphogenic protein-2 (BMP-2), alkaline phosphatase (ALP), runtrelated transcription factor 2 (RUNX2) and down regulating native smooth muscle
markers such as alpha smooth muscle actin (α-SMA), actin bundling protein transgelin or
SM-22α, smooth muscle myosin heavy chain (SM-MHC) and local calcification
inhibitors such as matrix gla proteins (MGP) and systematic inhibitors like fetuin-A [2,
12, 37-39]. The altered expression of these proteins has been shown to be positively
correlated to severity of calcification [12, 39, 40].
Previous medical perspectives on vascular calcification categorized it as a passive
age-related process, wherein calcified plaques in the arteries were considered benign
[23]. Existing correlations between vascular calcification and other non-age specific
complications like stroke, myocardial infarction, comprised cardiac perfusion and
impaired arterial dispensability have made it increasingly clear that vascular calcification
is not a passive process and depending on the severity it can have serious life threatening
consequences [23]. Once the relationship between vascular calcification and cardiacrelated morbidity and mortality had been established, the underlying mechanisms that
lead to vascular calcification began to be studied. The pathology of vascular calcification
has been paralleled to physiological bone formation [24] and is now regarded as an active
cell-mediated process involving, cell death, loss of mineral inhibiting factors, and
hydroxyapatite deposition in the underlying VSMC cell matrix similar to the mineral
metabolism that occurs in the assembly of skeletal bone [41]. Recognizing the
similarities between the processes of osteogenesis and ectopic calcification of soft tissue
organs spurred breakthroughs in vascular calcification research on new ways to treat the
4

disease. Key regulators in the skeletal biomineralization process have also been
identified to play a role in the development of vascular calcification [24]. Proteins
mediate bone growth and remodeling by actively inhibiting and promoting mineral
deposition and antagonizing cellular expression of bone forming proteins [6, 42-44].
Thus, understanding the mechanism(s) of regulatory proteins on mineral metabolism is
imperative for the development of successful protein- based therapies to effectively treat
and potentially reverse vascular calcification.
For patients with end-stage renal disease (ESRD), malnutrition, dietary
restrictions and the duration of dialysis treatments have shown a positive correlation with
the progression of medial calcification [45, 46] when compared to age matched healthy
controls, and non-uremic control groups [11, 17, 47-49]. We are proposing a novel
therapy of targeted protein delivery to remedy medial calcification in ESRD patients. As
heart healthy proteins like fetuin-A and MGP tend to be deficient and or under expressed
in ESRD patients, early administration of a protein based therapy during the course of
dialysis treatment is a viable therapeutic option. By directing fetuin-A protein release to
local sites of calcification and indirectly increasing local matrix gla protein expression,
we can treat vascular calcification. This drug delivery system could actively prevent the
formation of vascular calcification by halting the nucleation, growth, and aggregation of
hydroxyapatite crystals and rescue the vascular smooth muscle cell phenotype of the
affected arterial layer.
Systematic Inhibitor: Human Fetuin-A
In addition to the loss of VSMC phenotype, clinical studies of dialysis patients
revealed a negative correlation between existing vascular calcification and decreased
5

serum concentrations of fetuin-A, a well-known systematic inhibitor of extra-skeletal
calcification [12, 22, 50]. Low levels of serum fetuin-A are seen as predictors of
cardiovascular morbidity in patients with ESRD [22, 51], and more specifically correlate
with increased mortality in dialysis patients [29].
Fetuin-A, also known as alpha2-Heremans Schmid glycoprotein, is a
multifunctional serum protein that is naturally synthesized in the liver [52]. It acts as an
indicator of chronic inflammation; helps to regulate bone metabolism by antagonizing
transforming growth factor beta (TGF-β); provides over 50% of the inhibitory protective
effect from mineral precipitation in serum, and has the ability to act as a chaperone
protein by binding to and solubilizing calcium phosphate mineral colloids and facilitating
in their removal from the cells [30, 51, 53]. In a study by Shroff et al., immunostaining
revealed the presence of fetuin-A in the VSMCs of calcified arteries in patients with
kidney disease [12]. Literature shows that fetuin-A uptake by VSMCs is dependent on
extracellular calcium concentrations, and that under pathological concentrations of
calcium, fetuin-A uptake by VSMCs was significantly increased [12, 51]. This finding
indicates a potential role of fetuin-A in regulating mineralization outside of the skeletal
system, and sequestration of fetuin from serum may be part of a secondary inhibitory
response of the vasculature to the pathological calcification process [12, 51].
Local Inhibitor: Matrix Gla Protein
There are also local inhibitors of calcification that exert their function in the
tissues from which they are synthesized. One such group of proteins is MGP, which are
vitamin K dependent and primarily synthesized by VSMCs and chondrocytes [54].
Vitamin K is required to activate MGP via γ-carboxylation, a necessary modification that
6

enables MGP binding to BMP-2 [2, 38], thus inhibiting BMP-2 from exercising its
function as a bone forming protein.
In vivo studies by Luo et al on MGP deficient mice demonstrated the major role
of MGP to inhibit soft tissue calcification [55]. In the study, the mice exhibited severe
medial calcification leading to death at 8 weeks post-partum due to rupture of thoracic or
abdominal aorta. Due to dietary restrictions and certain medications like the vitamin Kantagonist Warfarin, given to dialysis patients there is insufficient vitamin K to activate
MGP. It is common for the inactive form, under carboxylated MGP (ucMGPs), to
accumulate in the VSMCs of dialysis patients [12]. This accumulation is often the nidus
for hydroxyapatite mineral growth [2, 56]. Medicinal prescriptions and dietary
restrictions are a common part of treatment for dialysis patients and unfortunately can
lead to mineral metabolism imbalance which has been shown to directly cause vascular
calcification in both clinical, in vivo and in vitro studies [35, 37]. It has been found that
conditions like hypercalcemia and hyperphosphatemia create a more acidic pH that is
conducive to soft tissue calcification [37, 57]. It has been shown that when the pH falls
below 7.4 MGP synthesis is increased [56]. In vitro calcification studies demonstrate the
ability of vitamin K treatments to reduce mineral deposits by over 60% from VSMC as
well as potentially rescue native SMC phenotype by restoring expression of native SMC
markers such as MGP and OPN [58].
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CHAPTER III
PROJECT OUTLINE

Research Hypothesis
Vascular calcification can be deadly depending on the organ systems affected and
the extent of calcification that is present. If the renal arteries are affected it can cause
disease and the loss of kidney function can likewise lead to mineral metabolism
imbalance that is further complicated by dialysis treatment. The altered mineral content
causes a lower pH and ultimately decreases the active form of mineral inhibitors in the
body, namely fetuin-A. As a result, serum fetuin-A which normally functions to prevent
mineral formation on blood is endocytosed by VSMCs to help prevent calcification in
soft tissues, causing the decrease in serum fetuin levels that is commonly found in
dialysis patients [12, 59]. Clinical restriction for CKD patients require special diets that
further promote calcification by limiting the necessary dietary vitamins needed for the
VSMC to create mineral antagonist proteins like MGP. The lack of native mineral
inhibitors present in serum and insufficient means to synthesize local inhibitory proteins
increase the development of vascular calcification. Due to the similarities between
skeletal bone and vascular mineral deposits, it has been proposed that vascular
calcification can be reversed via demineralization, in a fashion that mimics physiological
removal of calcified debris from bones [53].
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A targeted intravenous therapy of fetuin-A would effectively halt the formation,
growth, and aggregation of calcium minerals in the arteries; thus, preventing vascular
calcification and potentially reducing the incidence of cardiac-related mortality. Our goal
is to treat and prevent cardiovascular calcification in a minimally invasive manner that
uses the native circulatory system to deliver this protein-based therapy specifically to
sites of calcification. We are proposing a targeted protein therapy to prevent vascular
calcification with these specific aims:
Specific Aims
Aim 1: Characterize the binding mechanism, aggregation and stabilization effects of
fetuin-A on calcium carbonate nanoparticles.
Aim 2: Examine the inhibitory effect of a fetuin and vitamin K2 co-treatment to rescue
native vascular smooth muscle cell phenotype and prevent calcification in an in
vitro model.
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CHAPTER IV
PROTEIN-MINERAL COMPLEX FORMATION

Biomineralization as an active process: A role for proteins
Study of protein involvement in the biomineralization process have resulted in
new biomedical advances such as (i) targeted drug delivery systems (ii) dual purpose
procedures used to simultaneously diagnose disease and administer therapy ; and (iii)
development of biological stabilizers to optimize gene therapy and delivery of other large
biomolecules into cells and tissues [60]. It has been shown that the incorporation of
proteins and biomolecules with synthetic materials allows for increased biostability,
biocompatibility, and an increase in successful biointegration with natural systems [61].
Bone growth and remodeling are processes that rely on protein activity to either inhibit or
promote mineral deposition and other cell mediated activities. Understanding the
mechanisms between proteins and nascent mineral is key to developing efficacious
targeted protein therapies with the potential to treat vascular calcification.
Mechanism of Inhibition by human Fetuin-A
Fetuin-A has the ability to interact with mineral nuclei forming soluble colloidal
particles, which we will refer to as calciprotein particles (CPPs) [43]. Under
supersaturated mineral conditions fetuin-A prevents the precipitation of basic calcium
phosphate (BCP) thus acting as a potent inhibitor of extracellular calcification. At a
10

cellular level fetuin-A aids in preventing apoptosis of vascular smooth muscle cells;
however, the inhibitor protein can also aid in the binding of apoptotic bodies to
neighboring cells and facilitate in cellular resorption of CPPs [30, 53]. Clearance of
apoptotic bodies and CPPS reduces the potential for these bodies to act as a nidus for
BCP. To gain a better understanding on the mechanisms of CPP clearance and fetuin-A
function in stabilizing and solubilizing BCP colloids, researchers have studied fetuin-A’s
ability to form colloidal bodies under supersaturated concentrations of calcium and
phosphate in vivo and in vitro and in the affluent of peritoneal dialysis fluid. It has been
observed that fetuin-A prevents direct precipitation of BCP mineral into the crystalline
hydroxyapatite phase [43, 62]. Morphological changes in BCP mineral were observed by
electron microscopy, showing that the addition of fetuin-A resulted in a brittle
appearance of the precipitate formed [43]. The development of CPPs has been shown to
be a time-dependent process that involves two phases and results in changes in
appearance and an increase in diameter [62]. With regards to stability and formation
kinetics of CPPs, it was found that the concentration of fetuin-A used versus the mineral
ion concentration are factors that have a considerable effect on CPP size and the
secondary ripening transition phase. Changes in protein mineral exposure time, and
temperature resulted in feeble effects on subsequent CPP size [63]. A thorough
characterization of the fetuin-A protein and knowledge of its chelating properties will aid
in further understanding of its ability to control, stabilize and arrest the further
crystallization of biomineral polymorphs for the development of a protein therapy.
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Calcium Carbonate
Biominerals are naturally occurring organic-inorganic composites with a
controlled hierarchical structure. Small molecules and acidic proteins play an essential
role in the crystal lattice assembly of biomineral, ultimately determining the structure and
mechanism of formation. Ambiguities exist between the cellular cues and types of
proteins involved and the precise functions they play in controlling biomineral
architecture, polymorphism and overall morphology. Much of this ambiguity could be
resolved up by having a working knowledge and complete chemical analysis of the
involved protein(s) [64]. Despite complete biochemical analysis of molecular and
structural characterization of fetuin-A and extensive study of the various phases and
transition states of calcium carbonate there have been no experimental studies on fetuinA’s ability to stabilize calcium carbonate (CaCO3) [65, 66]. It is our aim to characterize
whether fetuin-A exhibits the same inhibition on biomineral precursors namely CaCO3
and to gain further understanding of acidic protein parts and their effects on
mineralization.
The objectives of this study were to characterize the biochemical interactions
between fetuin-A and calcium-based nanoparticles in a simulated body fluid by (i)
studying conformational changes of the protein upon binding to CaCO3 nanoparticles, (ii)
by confirming protein adsorption and binding with CaCO3 nanoparticles, and (iii) to
generate morphological identification of biocomposite systems for comparison/validation
of protein monolayer formation on CaCO3/CPP surface.

12

Experimental Section
Materials & Sample Preparation
Human fetuin-A was used as-received and reconstituted to a concentration of 0.1
mg/mL (Sigma-Aldrich, St. Louis, MO; Biovendor, Asheville, NC). After preparation,
Dulbecco’s modified Eagle’s medium (DMEM) (Corning, Lowell, MA) was filtered prior
to use with a cellulose nitrate 0.22 µm pore membrane (Corning) followed by a 0.1 µm
Acrodisc® Supor® membrane. DI water was used from an EMD Millipore Water
purification system (Type I reagent grade water). Calcium carbonate (CaCO3)
nanoparticles (15-40 nm) were used as-received and without any further modification
(SkySpring Nanomaterials, Inc., TX, USA). For the fetuin-A/CaCO3 particles used in this
work, DMEM was the solvent for all solutions. After two-stage DMEM filtering
procedures, a small aliquot of DMEM was examined with DLS to guarantee a zero
effective diameter. Then a solution with a concentration of 0.1 mg/mL of CaCO3 in
DMEM was prepared (4 mL). This solution was then filtered using an Acrodisc 1.2
micron Versapor membrane syringe filter, and sonicated for 5 minutes using a sonication
bath (VWR) without heating. After sonication, DLS measurements were performed and
the effective diameter of the sample was recorded. Fetuin-A protein (100 µL) was then
added, at a concentration of 100 µg/mL. This solution containing CaCO3 and fetuin-A in
DMEM was then studied using DLS, TEM, FTIR, XPS, UV-Vis, and SEM to examine
the formation and evolution of the fetuin-A/CaCO3 complexes.
Chemical Characterization
A Nicolet 6700 FTIR spectrophotometer (Thermo Electron Corporation) with a
He-Ne laser, MCT-A* detector, and KBr beam splitter with a Miracle-ATRTM accessory
13

(Diamond-ZnSe crystal, PIKE Technologies) was used for ATR-FTIR spectra collection.
Fetuin-A, CaCO3, and fetuin-A/ CaCO3 nanoparticle complexes samples were deposited
onto the ATR crystal from solution, the solvent was allowed to dry, leaving a thin sample
film on the crystal’s surface. Infrared spectral data was then collected and analyzed using
Omnic software (v8.1.10, 1992-2009, Thermo Fisher Scientific, Inc.), and a minimum of
256 scans collected for each sample. X-ray photoelectron spectroscopy (XPS) was
conducted using a PHI 1600 XPS surface analysis system (Physical Electronics, Mg Kα
X-ray source (300 W, 15 kV), 45° take-off angle, PHI 10-360 spherical capacitor energy
analyzer, and an Omni Focus II small-area lens. All samples were deposited from
solution onto a clean gold-coated silicon wafer substrate. A total of 10 scans with 26.95
eV pass energy across the 1100-0 eV range were analyzed for survey scans. Highresolution XPS spectra consist of a minimum of 25 scans, at a 23.5 eV pass energy and
0.1 eV step size. At least three spectra per sample were analyzed, and the averages are
reported. Data analysis was performed using Origin Pro 2015.
Morphological Characterization
Scanning electron microscopy (SEM) was performed using a JEOL JSM-6500
field emission scanning electron microscope (FE-SEM) operated at 10 keV. Sample
preparation was performed in a similar manner to the XPS analysis; however, the goldcoated silicon wafers were mounted on SEM holders using double-sided black carbon
tape. High-resolution transmission electron microscopy (TEM) images were obtained
using a JEOL 2100 at 200 kV. For TEM, sample droplets were placed on a carbon
Formvar Cu grid 300 mesh (Electron Microscopy Science), and the liquid was evaporated
14

at ambient conditions inside a fume hood. CryoTEM images were collected using a JEOL
1400 Biological TEM with a Gatan cryoplunge adapter.
In-situ Characterization of Particle Diameters
Dynamic light scattering (DLS) and zeta-potential phase-angle light scattering
(PALS) measurements were conducted using a ZetaPALS instrument (659 nm
wavelength, 90° detector, Brookhaven Instruments Corporation (BIC), Holtsville, NY).
At least 5 measurements were taken for each sample, including 30 measurement cycles
for each PALS experiment. Outlier analysis was performed at a 0.05 level of significance.
Samples were analyzed at ambient temperature conditions (~22 °C). Results reported are
based on Stokes-Einstein equation for the effective hydrodynamic diameter, or average
mean diameter by number, and is specified for each analysis.
Results
Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy (ATRFTIR)
The infrared absorption bands of the CaCO3 nanoparticles and fetuin-A protein
were characterized as-received, using ATR-FTIR to identify their chemical composition
Literature reports three distinct peaks for CaCO3 in a 100% calcite state [67]. Our
findings are concurrent with reported literature, as we have established the presence of
pure calcite by identifying the following bands and their respective calcite stretching
vibrations: 1426 cm-1 (ν3), 876 cm-1 (ν2) and 712 cm-1 (ν4), see Figure 4.1a.
Similarly, identifying peaks for neat fetuin-A were evaluated and to the authors
knowledge this is the first study to report ATR-FTIR characterization of fetuin-A. IR
analysis of proteins involves the detection of amide I, II and III spectral region [68].
15

Deconvolution of the infrared spectra for the neat fetuin-A protein and the fetuinA/CaCO3 reveal a loss in characteristic vibrations of the glycoprotein as seen in (Figure
4.1b-c). The differences in IR spectra of the amide complex bands between fetuin-A and
fetuin-A/ CaCO3 peaks will be discussed herein. Additional identification of other
characteristic peaks for the fetuin-A protein are discussed in Appendix Figure A.1 and
summary table of these bands is available in Appendix Table A.2. As seen in Figure 4.1b
an evaluation of the amide I region for the protein spectra reveals four distinct peaks in
the range of 1600-1700 cm-1 wavenumbers. The peaks observed at 1700 cm-1 and 1654
cm-1 correspond to the C=O stretching vibrations. Specifically the peak seen at 1700 cm-1
is indicative of glutamic acid or asparagine amino acids present in the protein [69]. The
α-helical secondary structure of the protein and/or the C=O stretching vibrations from the
arginine amino acids can be identified by the peaks seen at 1654 cm-1 which is typical of
soluble proteins [69-71]. Evidence of protein secondary structure was seen in the form of
peaks at 1629 cm -1 and 1601 cm -1 which correspond to protein β-sheets and
intermolecular β-sheet turns respectively [68, 69]. Analysis of the amide II region for
neat fetuin-A revealed an absorption peak at 1543 cm -1 which is indicative of a primary
amine deformation (Figure 4.1b) possibly occurring in tryptophan side chains [69, 72].
The peak at 1515 cm-1 represents C-O stretching in the alcohols of amino acid side chain
tyrosine [69, 72].
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Figure 4.1

ATR-FTIR spectra comparing neat fetuin-A, CaCO3 and fetuin-A/CaCO3
complex samples

A) ATR-FTIR spectra overlay for fetuin-A, CaCO3 and fetuin-A/CaCO3 complex
B) Deconvoluted spectra showing amide I and amide II region for neat fetuin-A
C) Deconvoluted spectra showing amide I and amide II region for fetuin-A/CaCO3
The addition of fetuin-A to CaCO3 nanoparticle samples resulted in notable
changes of the protein IR absorption peaks. The loss of two out of four peaks in the
amide I region indicate that binding of the protein to the CaCO3 nanoparticles imparted
changes in the proteins chemical structure. Upon combining the protein with the CaCO3
sample IR spectra revealed characteristic peaks of asparagine (C=O) amino acid groups at
1640 cm -1 and 1675 cm -1 [69], see Figure 4.1c. The loss of characteristic peaks in the
amide I region upon analysis of the fetuin-A with CaCO3 sample point to a potential
binding mechanism between fetuin-A and CaCO3 nanoparticles involving protein βsheets and loss of α-helical turns. FTIR analysis of proteins onto a biomaterial surfaces
reveal that β sheet vibrations tend to absorb between 1640 and 1620 cm-1 and that
absorbance readings ~1670cm-1 correspond to β-turns [70, 71]. Moreover bands in the
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1670-1695 cm-1 region correspond to anti-parallel β-sheet structure [71]. The peaks that
were lost in the neat fetuin-A analysis, 1654 cm-1, 1629 cm -1 and 1601 cm -1
wavenumbers, correspond to the amino acid residues of the protein secondary structure
[43]. The findings concluded by Heiss et al. revealed that it is the amino acid residues of
the fetuin-A protein that are responsible for the proteins affinity for calcium and in this
case the adsorption onto the CaCO3 nanoparticle substrate [43]. With regards to the
amide II region, comparison of the IR spectra for the fetuin-A with CaCO3 nanoparticles
and the neat fetuin-A sample shows both the loss of characteristic peaks within the amide
II region and a noticeable increase in wavenumber of the detected peak from 1543 cm-1 to
1586 cm -1. The changes in absorbance indicate the binding of fetuin-A to the CaCO3
substrate that resulted in changes to protein secondary structure as illustrated by loss of
absorbance of tyrosine and tryptophan amino acid side chains, 1515 and 1543 cm-1
respectively, and led to the detectable absorbance of amino acid glutamine (1586 cm-1)
[69, 70, 72, 73].
X-ray Photoelectron Spectroscopy
Elemental composition of the sample surface, namely CaCO3 and fetuin-A/
CaCO3, were evaluated using X-ray photoelectron spectroscopy (XPS). As expected
elemental surface analysis of the CaCO3 nanoparticles revealed carbon (C, 32.8 ± 3.1),
calcium (Ca, 18.4 ± 3.8%), and oxygen (O, 48.9 ± 0.9%) which were close to theoretical
values for CaCO3 composition (20% C, 20% Ca, and 60% O) and can be seen in Figure
4.2. The graph in Figure 4.2 shows an overlay of XPS results of elemental detection of
the CaCO3 and fetuin-A with CaCO3 samples. The deviation in the carbon content for the
elemental composition of CaCO3 nanoparticles is considered adventitious and is due to
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preparation of XPS samples in open air prior to analysis and can be otherwise neglected
[74]. Similarly elemental surface analysis of the fetuin-A/ CaCO3 samples revealed 61.4
± 0.6% C, 31.3 ± 0.8% O, and 7.3 ± 1.5% N. The detection of nitrogen and the increase
in the carbon content, despite the presence of adventitious carbon, indicates the addition
of glycoproteins, confirming the presence of fetuin-A on the surface of CaCO3 particles
[75]. The absence of elemental Ca within the outermost10 nm layer of fetuin-A/ CaCO3
sample surface suggesting that CaCO3 has been encased by a fetuin-A protein coat,
resulting in a stabilized fetuin-A/ CaCO3 complex structure.

Figure 4.2

Overlaid XPS scans for neat CaCO3 nanoparticles and fetuin-A/CaCO3
protein nanoparticle samples

Evident from the different IR spectra discussed previously, the formation of the
fetuin-A/ CaCO3 complex resulted in chemical changes in the protein structure. Highresolution XPS analyses of elemental calcium, carbon, oxygen and nitrogen enabled us to
identify specific functional groups and chemical bonds that were altered as a result of
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complex formation. In reference to calcium the high resolution scans can be seen in
Figure 4.3 A-B, showing the results for neat CaCO3 nanoparticles and for fetuin-A/
CaCO3 complex.

Figure 4.3

High resolution XPS scans for elemental calcium

A) Neat CaCO3 nanoparticle samples
B) Fetuin-A/CaCO3 protein and nanoparticle sample
For the neat CaCO3 nanoparticles, Figure 4.3A, there were two clearly identifiable
calcium peaks at 346.5 and 350.0 eV, which correspond to the Ca 2p3/2 and Ca 2p1/2
photoelectron lines, respectively [76, 77]. Upon analysis of the high resolution XPS
calcium scan for the fetuin-A/ CaCO3 complex a loss of the peaks correlating to the Ca
2p3/2 and Ca 2p1/2 photoelectron lines was observed (Figure 4.3B). The lack of
elemental calcium detected in the fetuin-A with CaCO3 sample seen in Figure 4.3
supports the hypothesis of the formation of a stabilized fetuin-A protein coat over the
CaCO3 nanoparticle surface. It is known that fetuin-A binds to calcium with high affinity
and the undetectable calcium in this XPS surface analysis supports our conclusion that
fetuin-A has adsorbed onto the CaCO3 nanoparticle surface. With regards to the other
elements, carbon, oxygen and nitrogen the high resolution XPS scans also indicate
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adsorption-related transitions in peaks associated with identifying photoelectron lines.
For carbon, see Figure 4.4 A-B, the C 1s peak at 285.3 eV corresponds to C-C/C-H bonds
and is found in both neat CaCO3 and fetuin-A/ CaCO3 complex samples respectively. In
order to calibrate the scans for charge compensation the C1s peak was used as a reference
[78]. For the neat CaCO3 sample the peak at approximately 290 eV represents carbonate
((C-O)3) from CaCO3 [76]. The additional high resolution carbon peaks at 286.8 eV and
at 288.7 eV observed for the fetuin-A/ CaCO3 sample (see Figure 4.4B) confirm the
presence of fetuin-A glycoprotein on CaCO3 particles. The peak at 286.8 eV is indicative
of C-O, C-N and/or to an N-C-O bond [73, 79]. The 288.7 eV peak represents N-C=O,
and is consistent with the carbon of an amide functional [79, 80].

Figure 4.4

High resolution XPS scans of elemental carbon and oxygen.

Carbon scan for (A) neat CaCO3 nanoparticles and (B) fetuin-A/ CaCO3 protein
nanoparticle samples
Oxygen for (C) neat CaCO3 nanoparticles and D) fetuin-A/ CaCO3 protein nanoparticle
samples.
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Results for the neat CaCO3 nanoparticle high-resolution oxygen scan (see Figure
4.4C) reveal a O 1s peak at 528 eV binding energy corresponding to carbonate ((C-O)3)
oxygen in CaCO3 [77]. Analysis of the fetuin-A/ CaCO3 sample (see Figure 4.4D) show
that complex formation resulted in two distinct chemical shifts for the high resolution
oxygen scan. The peak observed at 530.6 eV represents oxygen in amino acid chains
[81], and the 532 eV peak can be attributed to either a C=O peptide bond or to –OH
bonds which could be residual contaminants left after the solvent evaporated [82-85].

Figure 4.5

High resolution XPS for elemental nitrogen

(A) Neat CaCO3 nanoparticles
(B) Fetuin-A/ CaCO3 protein nanoparticle sample.
Lastly, the detection of a N 1s photoelectron line in the fetuin-A/ CaCO3 sample
and not in the neat CaCO3 high-resolution nitrogen scan confirms fetuin-A presence on
the outer surface of fetuin-A/ CaCO3 complexes (see Figure 4.5 A, B) [83]. The results of
these XPS data support those obtained from ATR-FTIR and indicate the presence of
fetuin-A on the exterior surface of fetuin-A/ CaCO3 samples, indicative of a stabilizing
protein coat on the mineral complex.
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Electron Microscopy
Morphological characterization show the CaCO3 nanoparticles have a tendency to
aggregate, this is likely due to the fact that the samples were allowed to dry on the grid
SEM grid without a stabilizer (see Figure 4.6 A). The CaCO3 nanoparticles showed a
rhomboid-like structure under SEM analysis (see Figure 4.6 B). The results obtained
from TEM (see Figure 4.7 A) corroborate those of SEM and show densely packed
clusters of aggregated CaCO3 nanoparticles. The rhombohedral shape is evident upon
higher magnification with TEM (Figure 4.7 B) and is representative of nanosized CaCO3
crystals within a larger-scale aggregated structure. These images of CaCO3 nanoparticle
morphology support those found in literature on aggregation of the mineral phase [86].

Figure 4.6

SEM image of neat CaCO3 nanoparticles.

Scale bar is equal to 10 µm and 1 µm for images A and B respectively.
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Figure 4.7

TEM images ofaggregated neat CaCO3 nanoparticles.

At high resolution a rhombohedral-like structure is observed which is characteristic of
nanoparticle materials. Scale bar is equal to 100 nm and 50 nm for images A and B
respectively
As discussed in the beginning of this chapter fetuin-A is said to absorb onto
aggregated CaCO3 to form a complex. Once fetuin-A protein is added to CaCO3 particles
the morphology changes and SEM images show protein-stabilized CaCO3 aggregates
(Figure 4.8 A, B) As seen in the same image, globular fetuin-A begins to adsorb onto the
CaCO3 nanoparticle aggregates and the resultant complexes range in size from 400-600
nm after a 48 hour incubation period. Interesting to note that the rhomboid like
morphology of the neat CaCO3 nanoparticles was lost, signifying transitions in the
crystalline phase of the CaCO3 particles.
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Figure 4.8

SEM images of CaCO3/fetuin-A protein nanoparticle complex samples.

The morphology shown here is move ovoid in appearance compared to neat CaCO3
nanoparticles and includes both large and small aggregates. Scale bar is equal to 1 µm
and 100 nm for images A and B respectively.
Research on calcium carbonate interactions with acidic protein residues have
determined that binding of the protein to the substrate occurs parallel to the calcium
plane, thus altering mineral morphology and giving it a smoother texture [87]. Studies
have shown that CaCO3 mineral microstructure can be dramatically altered by proteins to
generate various distinct crystalline phases [88]. Ultimately, the loss of rhombohedral
structure upon formation of fetuin-A/ CaCO3 complexes supports the de-aggregation and
stabilization CaCO3 particles when fetuin-A adsorbs onto the CaCO3 aggregate.
High resolution TEM analysis was employed in order to evaluate the morphology
within the protein mineral complexes formed. Detection of three distinct morphologies
depict possible intermediate stages of stabilized complex development and protein
binding interactions between fetuin-A and CaCO3 nanoparticle structures. The first
morphology depicted below (Figure 4.9A), is suggestive of an intermediate state in which
fetuin-A proteins are bound to small CaCO3 particles inducing phase transitions. The
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morphology observed in Figure 4.9A represents more stable complexes and has an ovoid
appearance which is supported by the morphology seen in SEM results and further
confirmed by the DLS results to be presented shortly (Figure 4.10 A, B). The next
morphology (see Figure 4.9B) that was observed shows needle like protrusions coming
from the corona of a lesser dense core with smaller CaCO3 particulates diffusing from the
exterior of the structure (see Figure 4.9B inset). Figure 4.9 C shows what we believe to
be CaCO3 particle aggregates encased by a stabilized protein coat.

Figure 4.9

Early, intermediate and stabilized stages of fetuin-A/CaCO3 protein
nanoparticle complex formation.

A) Early fetuin-A/CaCO3 complex formation
B) Intermediate stabilization stage of fetuin-A/CaCO3 complex formation; inset reveals
the solubilization of CaCO3 mineral by fetuin-A protein, scale bar = 200 nm.
C) Stabilized fetuin-A/CaCO3 protein mineral complex.
In situ characterization of Fetuin-A/ CaCO3 complexes
Analysis of the fetuin-A protein and fetuin-A/ CaCO3 complex molecular
absorbance and hydrodynamic diameter were assessed in situ using dynamic light
scattering (DLS) and UV-Vis spectroscopy while in an aqueous simulated body fluid
(DMEM). The DLS hydrodynamic diameter of the fetuin-A protein was 6 ± 0.74 nm in
DMEM (Figure 4.10 A,B), and relates well with literature reports of 4.2 nm for fetuin-A
corresponding to an ASHG monomer [89]. Number-averaged mean diameters for the
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protein samples were reproducible, as indicated by the plot intensity for multiple runs
(Figure 4.10B).

Figure 4.10

Fetuin-A stabilizes CaCO3 nanoparticles by forming a complex and
reducing hydrodynamic diameter of nanoparticle aggregates.

A) Average effective diameter increases significantly from the neat CaCO3 nanoparticle
aggregates to the fetuin-A/CaCO3 protein nanoparticle complex.
B) Number intensity readings of fetuin-A protein size are shown indicating protein
diameter stability in DMEM solvent.
The results for the effective particle diameter (using the Stokes-Einstein equation)
support the adsorption of fetuin-A onto the aggregated CaCO3 structures and ultimately
the formation of a fetuin-A/ CaCO3 complex. The increase in the effective diameter of
the CaCO3 nanoparticles from the adsorption of the fetuin-A protein can be seen in
Figure 4.10A. A stable zeta potential reading of -24.2 ± 1.8 mV for the surface CaCO3
particles was increased to (-0.1 ± 9 mV) upon addition of fetuin-A protein confirming the
fetuin-A adsorption process.
Using UV-Vis spectroscopy neat fetuin-A protein was compared to fetuin-A/
CaCO3 complexes in solution. As compared to neat fetuin-A, a minor shift in maximum
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molecular absorbance in the 270-280 nm region as well as a decrease in absorbance
maxima occurs as fetuin-A/ CaCO3 complexes form in water (Figure 4.11). UV-visible
spectroscopy absorption spectra in the ~270-280 nm region indicate that the disulfide
bonds and the aromatic amino acids (tryptophan and tyrosine) of the fetuin-A protein are
altered upon absorption of fetuin-A to the CaCO3 nanoparticles [90]. This data
corroborates the FTIR spectral data (see Figure 4.1) with the loss of the distinctive amide
II peaks (1515 and 1543 cm-1) which match corresponding absorbance readings for
tyrosine and tryptophan and literature findings that the amino acid residues in fetuin-A
are responsible for the protein affinity to calcium substrates [91, 92].

Figure 4.11

UV-Visible Spectroscopy of neat fetuin-A compared to fetuin-A/ CaCO3
complexes

To further examine the long term stabilizing effects of fetuin-A on CaCO3
agglomerates the particle morphologies were analyzed after two months with in situ TEM
to avoid artificial particle shrinkage/distortion due to drying effects. Figure 4.12,
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corresponding to the 2 month sample, shows small particles ranging from ~11-110 nm in
diameter; the range of sizes is possibly due to decomposition of CaCO3 nanoparticle
aggregates.

Figure 4.12

Cryo-TEM of fetuin-A/CaCO3 incubated for two months reveals small
stabilized complex aggregates.

Conclusion
With the study the adsorption, binding and stabilizing effects of fetuin-A protein
on CaCO3 nanoparticles have been demonstrated. Moreover, characterization of the
chemical and morphological changes that occur during the interaction between the acidic
protein and the CaCO3 substrate have been closely examined and reported herein. CaCO3
is an attractive biomaterial for potential use in biomedical applications. The results of this
study can help evaluate how varying levels of fetuin-A mediate pathological calcification
while in the presence of CaCO3 particles in addition to the well-known basic calcium
phosphate. Both the biochemical and structural characterizations of CaCO3, the
glycoprotein fetuin-A, and fetuin-A/ CaCO3 complexes provide a foundation for further
studies examining the functional groups and protein segments involved in short- and
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long-term interactions and stability of mineral growth and aggregation. The results of this
work confirm that fetuin-A is a potent stabilizer of calcium ions despite the absence of
phosphate ion, as has been purported elsewhere. The formation of a stabilized fetuin-A/
CaCO3 complex has been shown to be time-sensitive, with the mechanism including an
initial adsorption, followed by a complex stabilization period, and then destabilization
and solubilization of the mineral agglomerates. This mechanism has been explored using
FTIR and XPS for chemical characterization, SEM and TEM to examine the morphology
and structural changes, and DLS, cryo-TEM and UV-Vis for in situ characterization of
the complex formation and development. The results from this study support the potential
use of fetuin-A in the development of biomedical therapeutics targeting cardiovascular
and/or bone deformation diseases.
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CHAPTER V
FETUIN AND VITAMIN K2 ADDITIVES TO PREVENT VASCULAR
CALCIFICATION

Vascular calcification is a complex condition further complicated by comorbidities involving disorders of metabolism and age-related illness. Elevated serum
phosphate levels (>1.4 mM), hyperphosphatemia, is a common condition seen in CKD
patients and has been correlated to severity of vascular calcification [23]. There are many
factors to consider when assessing the pathological mechanisms that take place. The
underlying cellular matrix and surrounding cells involved in arteriosclerosis, as well as
phenotypic switching that occurs among the vascular smooth muscle cells make
assessment of the condition a difficult one to properly model. To this end, knock-out
animal models and in vitro cultures have been rather successful in identifying key
mediators in the vascular calcification process [3, 7-9, 93]. Increased phosphate levels
lead to the calcification of smooth muscle cells in vitro and cause increased expression of
osteogenic markers such as core binding factor alpha or RUNX2 and osteocalcin [94].
Phosphate levels are mediated via the sodium-dependent phosphate co-transporter
(NPC) protein. Blocking NPC function with an inhibitor has shown a dose-dependent
decrease in inorganic phosphate (Pi) induced calcification of smooth muscle cells [94].
The NPC protein is responsible for the resorption of the majority of phosphate filtered
through the glomerulus. The sodium potassium channels in turn are regulated by
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parathyroid hormone (PTH) which acts to excrete excess phosphate into the urine. With
progressive kidney disease, declining glomular filtration rates lead to a decrease
phosphorus excretions contributing to hypophosphatemia. The increased serum levels of
phosphorus cause a decrease in serum calcium levels that consequently contributes to an
increase in parathyroid production. As one or both ion levels of calcium and phosphorus
increase in serum an insoluble complex, hydroxyapatite forms [95].With significant
increases in calcification there is a loss in expression and or function of calcium receptors
that control levels of intracellular calcium [96]. For this study we will use Pi for the
development of an in vitro vascular calcification model to study the potential of potent
mineral inhibitors fetuin and matrix gla protein (MGP) (see Chapter II). Briefly, fetuin-A
deficiency is common in dialysis patients and low levels of fetuin correlate with
increased risk of cardiac related mortality in this patient population. Fetuin-A is a wellstudied systematic regulator of biomineralization and has a binding affinity for calcium
mineral. The fetuin-A protein has the ability to form protein mineral complexes and
solubilize basic calcium phosphate precipitates and aids in cellular clearance of mineral
debris [30, 51, 53]. Study of local mineralization inhibitors like MGP, show that MGP is
an antagonist of bone forming proteins and protects the native VSMC phenotype [2, 38].
Vitamin K2 is necessary for production of activated, mineral inhibiting MGP [2, 38]. As
vitamin deficiency and prescription blood thinners like Warfarin cause vitamin K2
deficiency in dialysis patients the inactivated forms of the MGP create nucleation sites
for mineral deposition [12, 56]. Further examination of the matrix vesicles of vascular
smooth muscle cells found protein mineral complexes containing basic calcium
phosphate fetuin-A and MGP. This study aims to (i) assess the extent to which
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calcification can be halted and or reversed, (ii) whether or not the fetuin and vitamin K2
co-treatments have an additive affect to rescue the native VSMC phenotype changes
induced by calcifying media. Restoration of inhibitory proteins to the system could
reestablish the protein and vitamin deficiencies in dialysis patients whilst preventing the
development of vascular calcification and reducing the risk of cardiac-related morbidity
and mortality. The combined treatment using two potent mineralization inhibitors (fetuin
and MGP indirectly) may also reverse calcification and possibly restore the cellular
functions of the VSMC by rescuing the native phenotype.
Experimental Section
Materials & Sample Preparation
VSMC Culture and Morphology. Primary human aortic vascular smooth muscle
cells (ATCC, Manassas, VA) of passage 6-8 were cultured in Dulbecco’s Modified
Eagles Medium (DMEM) with 10% Fetal Bovine Serum, and 1 %
penicillin/streptomycin). Cell morphology was visualized using light microscope. At
passage 8, cells were seeded into 6-well plates with 3 mL of standard growth medium per
well. Medium was changed every 2-3 days until cells reached 80% confluence in each
well at which the time point of the study began, marked day 0. Experimental groups were
given calcification medium (standard growth medium supplemented with 3 mM dibasic
inorganic phosphate (Pi) from days 0-7. On day 7, calcification medium was removed
from the experimental groups that then received protein treatments in the form of
standard growth medium supplemented with 10µM fetuin, 1µM vitamin K2, or both for
another 7 days (n=4). Control groups include VSMCs cultured with and without
calcification medium for 14 days. (n=4)
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Quantification of Mineral Deposition.
On day 14, samples were prepared for atomic absorption spectroscopy (AAS) in
order to quantify calcium content of the cell cultures. Cells were treated with 0.6 N HCl
for 24 hours. The HCL supernatant was prepared for atomic absorption analysis via
addition of nitric acid and potassium. The calcium content of the cell layer was
normalized to protein concentration using BCA Protein Assay Kit (Pierce, Waltham,
MA).
Alkaline Phosphatase activity.
Alkaline phosphatase (ALP) activity of cell supernatants was measured from day
7 and day 14 samples of all groups was measured using a Colorimetric Alkaline
Phosphatase Assay Kit (Abcam, Cambridge, MA). Absorbance of p-nitrophenyl
phosphate (pNPP) was read at 405 nm wavelength and results were normalized to
standards. Sample background controls were used in order to correct for the red color of
sample supernatant when interpreting the results of the colorimetric output.
Scanning Electron Microscopy.
Following treatment, cells were fixed with Karnovsky’s fixative in 0.1 M sodium
cacodylate buffer and then processed for imaging. Imaging was performed using a JEOL
JSM-6500 field emission scanning electron microscope (FE-SEM) operated at 10 keV.
Energy Dispersive X-Ray Spectroscopy (EDS) was used to quantify the elemental
composition of regions of interest.
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Statistical Analysis.
Comparison between control groups and experimental groups was performed
using ANOVA and post-hoc Tukey HSD.
Results
Quantitative Calcium Analysis
AAS was used to measure the amount of elemental calcium in the in vitro
cultures. Quantitative analysis of calcium content in cells was found by extrapolation
from the absorbance versus concentration plot obtained by the standard curve. The
amount of calcium deposited by the cells that calcified for the entire length of the study,
was significant when compared to all other groups including the 7 day calcified cells 14
day untreated (universal control) cells and the cells that received protein treatments
(10μM fetuin and or 1μM vitamin K2). There were no statistical differences observed
between treated groups and the universal control; however, the comparable level of
calcium content found in protein/vitamin treated cells and the universal control supports
the ability of fetuin and or vitamin K2 treatments to significantly inhibit calcification
when compared to cells exposed to only calcifying media, see Figure 5.1.
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Figure 5.1

Elemental calcium content of human vascular smooth muscle cells treated
with calcifying media and subsequent calcification inhibitors.

Protein Analysis
Alkaline phosphatase assay is designed to measure ALP activity, and is an early
bone indicator of alterations in VSMC native phenotype. The assay uses pNPP as a
phosphatase substrate that changes color when dephosphorylated by ALP. As seen in
Figure 5.2, ALP activity is highest on day 7 of VSMC exposed to calcifying media. The
day 14 universal control group that received standard growth media as well as the vitamin
K2 only treatment group have miniscule amounts of detectable ALP activity. Statistical
analysis of the ALP results showed that there was no significant variation among
treatments and controls using one-way ANOVA.
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Figure 5.2

Alkaline phosphatase activity in human vascular smooth muscle cells
treated with calcifying media and subsequent calcification inhibitors.

The results of this study further support the ability of fetuin and vitamin K2 to
prevent calcification and moreover the ability to rescue the native VSMC phenotype as
seen by the decrease in ALP activity from the first week of receiving calcifying media to
the second week of receiving media supplemented with calcification inhibitors (fetuin,
vitamin K2 and a co-treatment of fetuin and vitamin K2).
Microscopy
Scanning electron microscopy was used to visualize the calcium deposition.
Morphological characterization of the control, calcified and treated cell groups can be
seen in Figures 5.3-5.6 below. Characteristic morphology for the VSMC is observed in
the images as well as rounded nodules which appear to be apoptotic bodies or perhaps
excreted exosomes that may or may not have served as a nidus for calcium deposition.
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Figure 5.3

Electron microscopy image of healthy and calcified human vascular
smooth muscle cells at day 14.

Left image is of human vascular smooth muscle cells that received standard growth
medium for the entire length of the study. The cells on the right received calcification
media for the length of the study. Images taken at 3500x magnification, scale bar = 10
µm.

Figure 5.4

Electron microscopy image of calcified human vascular smooth muscle
cells treated with calcification inhibitors fetuin or vitamin K2.

Above images are of human vascular smooth muscle cells that received calcification
media days 0-7 of the study and were subsequently given standard media supplemented
with calcification inhibitors on day 8-14 of the study; (left) cells given fetuin
supplemented media and (right) vitamin K2 supplemented media. Images taken at 3500x
magnification, scale bar = 10 µm.
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Figure 5.5

Electron microscopy image of calcified human vascular smooth muscle
cells co-treated with fetuin/vitamin K2

After receiving calcification media days 0-7 of the study the cells were given standard
media supplemented with both calcification inhibitors on day 8-14 of the study; Images
taken at 3500x magnification, scale bar = 10 µm.
Energy dispersive X-ray Spectroscopy (EDS) was also performed on the SEM
samples the results of these EDS scans can be seen in Appendix Figures A.2-A.6.
Conclusion
This study confirms the potential use of fetuin-A or vitamin K2 for the effective
development of a protein based therapy to treat vascular calcification. It was
hypothesized that fetuin and vitamin K2 would have an additive effect in preventing and
or reversing calcification in cells exposed to calcifying media for one week and then
treated with a combination of calcification inhibitors for a subsequent week. From the
results of the AAS on calcium deposition alone, no conclusions can be drawn about the
additive effects of a fetuin/vitamin K2 co-treatment to synergistically reverse the amount
of calcium deposited. The respective protein treatments as well as the combined protein
treatment were significantly effective in halting further calcification of the vascular
smooth muscle cells.
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Though the effects of combined fetuin and vitamin K2 did not appear to have an
additive effect on reducing calcium deposition, the results of SEM images do show
promise of the co-therapy to remove calcium deposits in cells as the electron microscopy
images of the treated groups were comparable to the healthy control group. The protein
treated groups received calcifying media for one week prior to getting the respective
treatments of 10 μM fetuin and or 1μM vitamin K2. When comparing the ALP activity of
the 7 day calcified cells to the treated groups there is notable reduction in detectable ALP
activity. Moreover the cells that received calcifying media for an additional week 14 day
calcifying control also had higher trend in detectable ALP activity than all groups that
received protein treatments. The lack of statistical evidence to support the ALP results
warrants a larger sampling group for future studies. Whether or not fetuin and vitamin K2
co-therapy have the ability to rescue the native VSMC phenotype can unfortunately not
be concluded by the results obtained from the ALP assay, an indicator of early osteogenic
transition of VSMC. The SEM images support he results found from the atomic
absorption spectroscopy where the fetuin and vitamin K2 treated groups are comparable
to the universal control and show significantly less deposits than the calcified VSMC.
The overall results support the feasibility of a fetuin therapy to have a potent
effect on vascular calcification. Adverse effects of this protein/vitamin co-treatment is not
expected since: (i)this study models the toxicological aspect of restoring fetuin protein
concentration and vitamin K2 levels to that of normal physiological levels and (ii) most
CKD patients have protein and vitamin K2 deficiencies which positively correlate to the
severity and progression of cardiac-related morbidity and mortality.. None the less it
would be interesting to observe how well this co-therapy would affect vascular
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calcification at the cellular level in a uremic model with serum starved cells. To this end,
the potential for further development of this project will be discussed in the next chapter.
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CHAPTER VI
FUTURE WORKS

Effective therapies have the ability to both treat and prevent the occurrence of
diseases. The work presented in this thesis shows that a co-treatment of fetuin and
vitamin K2 has the potential to be highly effective at preventing the progression of
calcification. In order to determine the potential of this therapy to effectively treat
vascular calcification, a thorough analysis of VSMC phenotype before and after therapy
is necessary. The work herein could be further enhanced by making the following
recommendations:
Expand the experimental design to include:

1.
a.

Pharmacological study where treatment groups receive incremental amounts
of fetuin and vitamin K2 treatment to determine the effective dose and to
examine the effect of low vs high dose on the ability to treat calcification.

b.

Treatments applied at varying time points in the calcification study before
calcification occurs during calcification and after the cells have calcified for a
longer period of time in order to compare the ability of treatment groups to
reverse calcification after one and two weeks of receiving inorganic
phosphate supplemented media.

c.

Develop a uremic model of vascular calcification to test the effective ness of
a fetuin/vitamin K2 co-treatment to properly model vascular disease in
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patients with chronic and or end-stage renal disease. Serum starve cells prior
to treatment to properly mimic a malnourished/ protein deficient state.
2.

Study Osteogenic Transition/Rescue of Calcified Vascular Smooth Muscle
Cells
a.

Perform Western blot analysis after cells have received treatment to assess
the ability of fetuin and vitamin K2 to restore native VSMC phenotype and
reduce the expression of osteogenic markers like RUNX2 and native VSMC
phenotype markers like MGP and SM α-actin.

b.

Isolate native protein-mineral complexes from cell culture supernatant
before, during and after calcification and protein treatments to characterize
fetuin-mineral complexes [97, 98].

In order to progress to an actual clinical therapy, this project must be further
developed to include delivery mechanisms sufficient for in vivo testing. If fetuin delivery
is to be developed into a therapy it is essential that this multifunctional protein be
encapsulated in a delivery vehicle. Protein delivery systems made of self-assembling
polymersomes are ideal carriers for targeted protein therapy. Variations of polymer block
combinations of polyethylene glycol and poly ɛ-caprolactone (PEG-b-PCL) grafted with
a stimuli responsive polymer are a common choice for developing targeted protein
therapies due to the biocompatibility, biodegradability and tailorability. With regards to
arteriosclerosis and the local changes in pH associated with the disease, a pH sensitive
polymer system containing an amino residue such as (β-amino ester) PAE or (poly
dimethyl amino ethyl methacrylate) PDMAEMA would be an ideal candidate for
developing a delivery vehicle for fetuin therapy The slightly acidic local environment,
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characteristic to arteriosclerosis, could be used as a stimulant for protein release. Taking
advantage of the unique ability of polymersomes to encapsulate hydrophilic compounds
within their core and simultaneously have active moieties such as antibodies, proteins,
vitamins, carbohydrates and more conjugated to their surface [99], we could direct the
release of fetuin-A to sites of calcification.
There are several options for moving forward with this project. As the acidic
residues of fetuin are responsible for binding with calcium mineral [83], protein
modification is a plausible avenue to pursue in attempts to make fetuin-A therapy even
more effective at removing unwanted mineral and or aiding in the ability of the protein to
solubilize the mineral component. Biochemical modification of proteins (i.e. amination)
may be the key to enhance fetuin-A ability to bind calcium mineral and increase its
stabilizing effects on mineral growth without compromising the proteins native ability for
cellular uptake and clearance of mineral complexes [100].
Though the focus of this thesis work has centered on utilizing the acidic residues
of the protein and the slightly acidic microenvironment as a stimulus for targeting and
release of a fetuin/MGP therapy other options do exist. As fetuin is sequestered to areas
of vascular calcification naturally one group of researchers have developed fluorescently
labeled fetuin to be used as a diagnostic for detecting calcified lesions [101]. In vivo
studies have already shown much promise for the use of Alexa fluor tagged fetuin protein
to detect calcification. The fluorescently labeled fetuin was successfully injected into the
arteries of atherosclerotic mice models and upon excision of the arteries was detected in
the tunica media of the carotid arteries [100, 101]. In addition to the novel use of fetuin to
diagnose and detect calcification, this study is proof that an injectable fetuin therapy
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would work to target arteriosclerosis. Further development of the therapeutic aspect of
fetuin could be coupled with this existing bioluminescence to develop a theranostic use of
fetuin for effective treatment of vascular calcification.
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APPENDIX A
ADDITIONAL SPECTROSCOPY ANALYSIS
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Fourier Transform Infrared Spectroscopy of Fetuin-A Protein
A summary on the finding of infrared absorption characterization for Fetuin-A are
displayed in Figure A.1 with specific functional groups summarized in Table A.2. The
broad band corresponding to primary amine symmetric/asymmetric stretch vibration was
identified near ~3300 cm-1. This band is characteristic of glycoproteins (i.e. fetuin-A)
(69). The peaks seen at 2960 ad 2935 cm-1 are representative of asymmetric and
symmetric –CH2 methylene absorption bands (69). More methylene absorption bands
were seen in the fingerprint region, as indicated by peaks at 1453, 1379, and 860 cm-1.
Infrared regions of interest for protein identification are that of Amide I, II and III. For
the fetuin-A spectra the amine I band was identified at 1652 cm-1 which can be attributed
to C=O stretching vibrations and is useful in determining alterations on protein secondary
structure (69). The Amide II and II regions for fetuin-A were observed at 1547 and 1238
cm-1 wavelengths respectively. The Amide II and III bands are primarily caused by the
respective N-H deformation and C-N stretching vibrations (69).
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Figure A.1

ATR-FTIR spectrum for neat fetuin-A protein with primary peaks
identified.
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Table A.1

Corresponding band assignments for neat Fetuin-A FTIR spectra.

Assignment

Origin

Absorption Band (cm-1)

H-C(COOH), out-of-plane bending
deformation

C–H

860

Primary amine, stretch, secondary αcarbon of amino acids

C–N

1034

Primary amine, stretch, primary αcarbon of amino acids

C–N

1078

Saturated secondary alcohol,
deformation

O–H

1125

Saturated tertiary alcohol, deformation

O–H

1153

Amide III band, secondary amine

N–H

1238

–CO stretch, carboxylic acids or
primary alcohols

C–O

1272

–CH3 symmetric in-plane bending
vibration

C–H

1379

–CH2 deformation, symmetric stretch,
–CH3 asymmetrical bending vibration.

C–H

1453

Amino acid chain absorption, tyrosine,
tyr–OH

C–O

1515

Amide II band, N–H deformation

N–H

1547

Primary amine, deformation

N–H

1634

Amide I band, carbonyl stretch

C=O

1652

–CH3 symmetric stretch

C–H

2875

–CH2 symmetric stretch

C–H

2935

–CH2 asymmetric stretch

C–H

2960

N–H / O–H

≈ 3400 - 3300

Primary amine, symmetric and/or
asymmetric region. O–H stretching
vibrations
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Energy Dispersive X-ray Spectroscopy of Calcified Human Vascular Smooth
Muscle Cells
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EDS mapping for the universal control human vascular smooth muscle
cells.

Figure A.2

Elemental composition of Carbon, Oxygen and Nitrogen were detected at 72.54, 9.98,
and 17.47 [wt. %].
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EDS mapping for the calcified human vascular smooth muscle cells.

Elemental composition of Carbon, Oxygen and Nitrogen at 61.00, 16.14, and 22.86 [wt.
%].
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EDS mapping for the fetuin treated human vascular smooth muscle cells.

Figure A.4

Elemental composition of Carbon, Oxygen and Nitrogen at 62.59, 13.13, and 24.29 [wt.
%].
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EDS mapping for the vitamin K2 treated human vascular smooth muscle
cells.

Elemental composition of Carbon, Oxygen and Nitrogen at 66.01, 12.87, and 21.12 [wt.
%].
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EDS mapping for the fetuin/vitamin K2 treated human vascular smooth
muscle cells.

Elemental composition of Carbon, Oxygen and Nitrogen at 66.92, 14.26, and 18.82 [wt.
%].
The results of the EDS (Figures A.2-A.6) did not show any detection of elemental
calcium, though various areas of interest were analyzed. Nevertheless, the initiation of
mineral deposition involves exosomes, and matrix vesicles that contain unstable protein
mineral complexes. It is plausible that the fetuin and vitamin K2 treatments have formed
stabilized protein mineral complexes around nascent biomineral therefore the deposits are
visible in SEM but protein binding to calcium content prevents elemental detection of
calcium mineral via EDS.
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